Home › Compare › BRIBF vs PLD

BRIBF vs PLD: Dividend Comparison 2026

BRIBF yields 1062.70% · PLD yields 3.18%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BRIBF wins by $32084457.49M in total portfolio value
10 years
BRIBF
BRIBF
● Live price
1062.70%
Share price
$0.19
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32084464.00M
Annual income
$27,073,008,093,454.87
Full BRIBF calculator →
PLD
PLD
● Live price
3.18%
Share price
$128.78
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.50M
Annual income
$5,256,436.18
Full PLD calculator →

Portfolio growth — BRIBF vs PLD

📍 BRIBF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBRIBFPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BRIBF + PLD cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
BRIBF pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BRIBF
Annual income on $10K today (after 15% tax)
$90,329.44/yr
After 10yr DRIP, annual income (after tax)
$23,012,056,879,436.64/yr
PLD
Annual income on $10K today (after 15% tax)
$270.62/yr
After 10yr DRIP, annual income (after tax)
$4,467,970.75/yr
At 15% tax rate, BRIBF beats the other by $23,012,052,411,465.89/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BRIBF + PLD for your $10,000?

BRIBF: 50%PLD: 50%
100% PLD50/50100% BRIBF
Portfolio after 10yr
$16042235.25M
Annual income
$13,536,506,674,945.52/yr
Blended yield
84.38%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

BRIBF
No analyst data
Altman Z
19.2
Piotroski
2/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+5.6% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BRIBF buys
0
PLD buys
0
No recent congressional trades found for BRIBF or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBRIBFPLD
Forward yield1062.70% ✓3.18%
Annual dividend / share$2.00$4.10 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4% ✓
Portfolio after 10y$32084464.00M ✓$6.50M
Annual income after 10y$27,073,008,093,454.87 ✓$5,256,436.18
Total dividends collected$31704729.30M ✓$6.37M
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: BRIBF vs PLD ($10,000, DRIP)

YearBRIBF PortfolioBRIBF Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$116,970$106,269.93$11,255$555.24+$105.7K → BRIBF
2$1,286,876$1,161,718.25$13,062$1,018.59+$1.27M → BRIBF
3$13,321,776$11,944,818.28$15,903$1,926.67+$13.31M → BRIBF
4$129,817,926$115,563,625.92$20,839$3,823.32+$129.80M → BRIBF
5$1,191,375,681$1,052,470,500.56$30,464$8,166.08+$1191.35M → BRIBF
6$10,301,704,979$9,026,933,000.21$52,054$19,457.30+$10301.65M → BRIBF
7$83,971,400,363$72,948,576,035.34$109,886$54,188.93+$83971.29M → BRIBF
8$645,568,504,677$555,719,106,288.88$304,030$186,451.18+$645568.20M → BRIBF
9$4,683,603,649,023$3,992,845,349,018.69$1,166,125$840,813.32+$4683602.48M → BRIBF
10$32,084,463,997,910$27,073,008,093,454.87$6,504,190$5,256,436.18+$32084457.49M → BRIBF

BRIBF vs PLD: Complete Analysis 2026

BRIBF — Stock

Brii Biosciences Limited engages in the development of medicines for the treatment of infectious and central nervous system diseases. The company develops BRII-778 and BRII-732, which are in phase I clinical trials for the treatment of HIV patients; BRII-179 and BRII-835, which are in Phase 2 to evaluate the combination of these two HBV mechanisms for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 1b/2a; BRII-835, which has completed Phase-2 for patients with chronic HBV infection; and Amubarvimab/romlusevimab combination therapy for the treatment of COVID-19. It also develops BRII-296 for the treatment of PPD; BRII-297 for treatment of various depressive disorders; BRII-636, BRII-672, and BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections; and BRII-658 for the treatment of MDR/XDR tuberculosis and non-tuberculosis mycobacteria. The company was incorporated in 2017 and is based in Beijing, China.

Full BRIBF Calculator →

PLD — REIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this BRIBF vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BRIBF vs SCHDBRIBF vs JEPIBRIBF vs OBRIBF vs KOBRIBF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.